The Power and Potential of Psychedelics in Healthcare: A Podcast Summary
DISCLAIMER: PLANETARY HEALTH FIRST MARS NEXT: does not necessarily support the views of guests, participants, or organizations. We do support a robust and dynamic community to accelerate conversations in health to lead to greater impact, awareness and making people’s lives better.
Introduction
Welcome to the Planetary Health First, Mars Next podcast, where we explore groundbreaking topics in health and wellness. In our recent episode, we had the privilege of hosting Christine Caldwell, founder and executive director of the End of Life Psychedelic Care Foundation. Christine shared her insights on the evolving field of psychedelic therapy, particularly its applications for end-of-life care, depression, PTSD, and traumatic brain injury (TBI).
Overview of Psychedelics in Healthcare
Christine Caldwell’s journey into psychedelic advocacy began with a focus on the safe and supported use of these substances, particularly for individuals facing terminal diagnoses. Her nonprofit aims to educate the public and professionals about the potential benefits of psychedelics, advocate for their safe use, and connect practitioners and patients through a supportive network.
Current Landscape and Research
Psychedelic research is gaining traction, with institutions like Johns Hopkins and NYU leading the charge. Key studies began emerging around 2016, focusing on substances like psilocybin. Historical research from the 1950s and 60s primarily involved LSD, but modern studies favor psilocybin due to its shorter duration and manageable effects. Psilocybin has shown promise in reducing anxiety and existential distress in terminally ill patients, providing a profound sense of peace and acceptance.
Key Psychedelics Discussed
Psilocybin: Known for its mystical and gentle effects, psilocybin is the most researched psychedelic for end-of-life care. It helps patients confront their mortality and reduce anxiety, as seen in the case of Thomas, a Canadian patient with stage four colon cancer who experienced significant anxiety relief through psilocybin journeys.
Ketamine: Legally used across North America and Europe, ketamine is a dissociative anesthetic that separates the mind from the body, allowing patients to observe their conditions objectively. It’s particularly effective for depression and chronic pain, providing a sensation of "dying before you die" which can alleviate the fear of death.
MDMA: Commonly known as ecstasy or molly, MDMA is expected to gain FDA approval for PTSD treatment due to its heart-opening effects, which promote self-compassion and empathy. It's especially beneficial for improving relationships and resolving internal conflicts.
5-MeO-DMT: Also called the "God molecule," this psychedelic offers a brief but intense journey into collective consciousness. It's suitable for patients close to death who seek a profound spiritual experience.
Ibogaine and Ayahuasca: Although not typically recommended for end-of-life care due to their physical toll, these substances are explored for their potential in treating addiction and PTSD, particularly in veterans.
Additional Resources:
A Conversation with Mary Telliano
EOLPC hosts Mary Telliano, an EoL Doula, Psychedelic Facilitator and Teacher with 10 years' experience accompanying hundreds of people through deep plant medicine journeys. Her approach is to show her clients how to trust their inner guidance so they can access their internal wisdom and intuition. For anyone interested in serving people toward the end of life, from a terminal diagnosis to days before transitioning, you will find this conversation illuminating. We cover different sacred medicines, dosing, holistic practices, and what the preparation, the journey and integration are like for people at this stage of life.
An Introduction to End of Life Psychedelic Care
This online, 90 minute presentation is designed for anyone interested in how psychedelics can benefit those faced with a life-threatening or terminal diagnosis. We explore how psilocybin, ketamine, and MDMA, as the most widely available and researched psychedelics, have helped thousands of people find peace and equanimity in their death and dying process. We cover the research, health considerations, how to work with them at end of life, and share a number of real-life stories which really explains why this work is so important.
Challenges and Advocacy
The adoption of psychedelics in mainstream healthcare faces several hurdles:
Regulatory Barriers: Over-regulation and the backlog of applications, such as those with PJM Interconnection, slow down the integration of renewable energy projects and similarly impact psychedelic research.
Health Considerations and Contraindications: Certain health conditions, such as uncontrolled high blood pressure, severe asthma, or pre-existing psychosis, may preclude the safe use of psychedelics.
Drug Interactions: Interactions with medications like lithium and SSRIs need careful management.
Advocacy and Education
Christine emphasizes the importance of advocacy at both state and federal levels. Legislation is pending in numerous states, and there’s bipartisan support for psychedelic therapy for veterans. Public education and professional training are crucial for advancing the field and ensuring equitable access to these treatments.
Advancements and Future Potential
The latest advancements in psychedelic research offer hope for new therapeutic approaches to mental health issues:
Clinical Trials: Ongoing studies are exploring the efficacy of psychedelics in treating various conditions. For instance, MDMA is in Phase III trials for PTSD, and psilocybin is being studied for its impact on depression and chronic pain.
Neuroplasticity and Cognitive Resetting: Psychedelics may promote neuroplasticity, allowing the brain to form new connections and pathways, which can lead to lasting changes in thought and behavior patterns.
Integration into Mainstream Healthcare: Efforts are underway to include psychedelics in insurance coverage and develop reimbursement models, making these treatments more accessible.
How You Can Advocate
Stay Informed: Follow the latest research and advancements in psychedelic therapy. Resources like ClinicalTrials.gov provide comprehensive listings of ongoing studies.
Support Legislation: Advocate for laws that support the safe and supported use of psychedelics. Engage with local and federal representatives to promote equitable access to these treatments.
Education and Training: Consider professional training in psychedelic-assisted therapy, particularly if you work in healthcare, mental health, or end-of-life care.
Community Involvement: Join or support organizations that advocate for the therapeutic use of psychedelics, such as the End of Life Psychedelic Care Foundation.
Conclusion
Psychedelics hold significant potential for transforming healthcare, particularly in treating mental health conditions and providing comfort at the end of life. While challenges remain, the growing body of research and advocacy efforts are paving the way for broader acceptance and integration of these powerful therapies.
Resources and References
ClinicalTrials.gov: Clinical Trials on Psychedelics
End of Life Psychedelic Care Foundation: EOLPC.org
Heroic Hearts Project: Heroic Hearts Project
MAPS (Multidisciplinary Association for Psychedelic Studies): MAPS.org
Thought Leaders and Experts
Dr. Roland Griffiths: Renowned researcher in psychedelic therapy, particularly psilocybin.
Dr. Nolan Williams: Expert in the therapeutic applications of psychedelics for PTSD and TBI.
Rick Doblin: Founder of MAPS and a leading advocate for psychedelic research and therapy.
By staying informed, supporting advocacy efforts, and engaging with the community, we can help unlock the full potential of psychedelics in healthcare and improve the quality of life for countless individuals.
Ep 93 Death, Dying and Psychedelics with Christine Caldwell